{"nct_id":"NCT05232071","title":"Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus","status":"COMPLETED","status_verified_date":"2024-07","start_date":"2022-06-29","start_date_type":"ACTUAL","primary_completion_date":"2024-03-30","primary_completion_date_type":"ACTUAL","completion_date":"2024-06-04","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["IVA"]}